

Group A streptococcal pharyngitis

David H. Darrow, MD, DDS,* and E. Stephen Buescher, MD[†]

The group A *Streptococcus* is the most common bacterial cause of pharyngitis. Although most cases of streptococcal pharyngitis are managed by primary care providers, the otolaryngologist is often consulted to assist in the management of patients with persistent sore throat, chronic streptococcal carriage, recurrent streptococcal pharyngitis, or complications of streptococcal infection. This article reviews recent advances in diagnosis and management of individual episodes of streptococcal pharyngitis, the clinical approach to the streptococcal carrier, and the role of tonsillectomy in the management of recurrent pharyngotonsillitis. *Curr Opin Otolaryngol Head Neck Surg* 2002, 10:449–454 © 2002 Lippincott Williams & Wilkins, Inc.

*Departments of Otolaryngology-Head & Neck Surgery and Pediatrics, and
[†]Division of Pediatric Infectious Diseases, Eastern Virginia Medical School, Children's Hospital of The King's Daughters, Norfolk, Virginia, USA.

Correspondence to David H. Darrow, MD, DDS, Department of Otolaryngology-Head & Neck Surgery, Eastern Virginia Medical School, 825 Fairfax Avenue, Norfolk, VA 23507, USA; e-mail: darrowdh@chkd.com

Current Opinion in Otolaryngology & Head and Neck Surgery 2002, 10:449–454

Abbreviations

ASO anti-streptolysin O
GABHS group A beta-hemolytic *Streptococcus*
PANDAS pediatric autoimmune neuropsychiatric disorder associated with group A streptococcal infection

ISSN 1068–9508 © 2002 Lippincott Williams & Wilkins, Inc.

The group A beta-hemolytic *Streptococcus* (GABHS) is the most common bacterium associated with pharyngitis in children. In the half-century since the advent of antibiotics, most pharyngeal infections by GABHS have been benign, self-limited, and uncomplicated processes. In fact, many patients improve symptomatically without any medical intervention whatsoever. However, a small number of affected individuals continue to develop severe disease such as streptococcal necrotizing fasciitis, and sequelae such as renal and cardiac complications, following GABHS infection. In addition, there is evidence that early antibiotic therapy may be useful in the treatment of GABHS. As a result, appropriate diagnosis and treatment of these infections is imperative.

Epidemiology

The incidence of GABHS pharyngitis has not been estimated on the basis of population-based data [1]. Nevertheless, strep throat is well recognized as a common disease among children and adolescents. The incidence peaks during the winter and spring seasons, and is more common in cooler, temperate climates. Close interpersonal contact in schools, military quarters, dormitories, and families with several children appears to be a risk factor for the disease.

Transmission of GABHS is believed to occur through droplet spread. The risk of contagion most likely depends upon the inoculum size and the virulence of the infecting strain. As a result, individuals are most infectious early in the course of the disease. The incubation period is usually between 1 and 4 days; however, antibiotics rapidly suppress the infection and most physicians will allow affected children to return to school 36 to 48 hours after antimicrobial therapy is started. The role of individuals colonized with GABHS in the spread of the disease is uncertain, although data suggest that carriers rarely spread the disease to close contacts [2]. Available data do not support the notion that the disease may be transmitted by pets [3].

Pathogenesis

The streptococci are gram positive, catalase-negative cocci, characterized by their growth in long chains or pairs in culture. These organisms are traditionally classified into 18 groups with letter designations (Lancefield groups) on the basis of the antigenic carbohydrate component of their cell walls. While the group A beta-hemolytic *Streptococcus* is isolated from most patients with streptococcal pharyngitis, group C, G, and B strep-

tococci may also occasionally cause this disorder. Unlike GABHS, however, these organisms are not associated with nonsuppurative sequelae. Further subclassification of streptococci is made based on their ability to lyse sheep or horse erythrocytes in culture; the beta-hemolytic strains cause hemolysis associated with a clear zone surrounding their colonies, while alpha-hemolytic strains cause partial (green) hemolysis and gamma-hemolytic strains cause no hemolysis.

Infection by GABHS requires adherence of the organism to pharyngeal and tonsillar epithelium. Attachment is accomplished by the fimbriae, which are fingerlike projections from the cell wall of the organism. However, resident alpha-hemolytic or viridans streptococci may compete with GABHS, inhibiting the establishment of infection to some degree [4]. The predilection of GABHS to affect the pharynx and other particular body sites has yet to be explained.

The *modus operandi* of GABHS can include classical suppurative, toxin-mediated, and/or immune-mediated mechanisms. The primary determinant of streptococcal pathogenicity is an antigenically distinct protein known as the M protein, which is found within the fimbriae. Using gene sequencing techniques, more than 120 M serotypes are now known [5], and it is likely that many more exist that are not yet characterized. Numerous serotypes circulate simultaneously within a selected population; in most cases, those associated with pharyngitis are different from those associated with impetigo or pyoderma. Strains causing pharyngitis in one individual may cause invasive disease when transmitted to other individuals [6•]. The M protein of the *Streptococcus* allows the organism to resist phagocytosis in the absence of type-specific antibody. In the immunocompetent host, the synthesis of type-specific anti-M and other antibodies, which belong primarily to the IgG class of immunoglobulins, confers long-term serotype-specific immunity to the particular strain in question. In laboratory-produced penicillin-resistant strains of GABHS, the M protein is absent, thereby rendering these strains more vulnerable to phagocytosis [7]. This finding may help to explain why there have been no naturally occurring penicillin-resistant GABHS isolated in more than 50 years of penicillin use.

GABHS are capable of elaborating at least 20 extracellular substances that affect host tissue; the interested reader may find a complete discussion of these substances elsewhere. Among the most important are streptolysin O, an oxygen-labile hemolysin, and streptolysin S, an oxygen-stable hemolysin, which lyse erythrocytes and damage other cells such as myocardial cells. Streptolysin O is antigenic, while streptolysin S is not. GABHS also produce three erythrogenic or pyrogenic toxins (A, B, and C) whose activity is similar to that of

bacterial endotoxin. Other agents of significance include exotoxin A, which may be associated with toxic shock syndrome, and bacteriocins, which destroy other gram-positive organisms. Spread of infection may be facilitated by a variety of enzymes elaborated by GABHS that attack fibrin and hyaluronic acid.

Clinical features

Signs and symptoms of GABHS pharyngotonsillitis vary from mild sore throat and malaise (30 to 50% of cases) to high fever, nausea and vomiting, and dehydration (10%) [8]. The disorder is acute in onset, usually characterized by high fever, odynophagia, headache, and abdominal pain. The pharyngeal and tonsillar mucosa are typically erythematous and occasionally edematous, with exudate present in 50 to 90% of cases. Cervical adenopathy is also common, seen in 30 to 60% of cases. Most patients improve spontaneously in 3 to 5 days, unless otitis media, sinusitis, or peritonsillar abscess occur secondarily.

Sequelae

The risk of rheumatic fever following GABHS infection of the pharynx is approximately 0.3% in endemic situations, and 3% under epidemic circumstances [8]. A single episode of rheumatic fever places an individual at high risk for recurrence following additional episodes of GABHS pharyngitis. Acute glomerulonephritis occurs as a sequela in 10 to 15% of those infected with nephritogenic strains [8]. In patients who develop these sequelae, there is usually a latent period of 1 to 3 weeks.

Recently, PANDAS (pediatric autoimmune neuropsychiatric disorder associated with group A streptococcal infection) has been recognized as an immune-mediated illness associated with GABHS infection, similar to Sydenham's chorea. In a recent prospective study identifying children with PANDAS, the most common presentation was the abrupt onset of severe obsessive-compulsive disorder behaviors including hand washing, preoccupation with germs, and daytime urinary urgency or frequency in the absence of infection [9•]. These behaviors resolved with treatment of the accompanying sentinel GABHS pharyngitis. Recurrence of obsessive-compulsive behaviors were seen in 50% of patients reinfected with GABHS and resolved with antibiotic treatment. The disorder has recently been reviewed in the otolaryngology literature [10••].

Diagnosis

Early diagnosis of streptococcal pharyngitis has been a priority in management of the disease, primarily due to the risk of renal and cardiac sequelae. A number of authors have studied the predictive value of various combinations of signs and symptoms in an effort to distinguish streptococcal from nonstreptococcal pharyngitis; however, none of these has been particularly reliable. Taken together, these studies demonstrate a false nega-

tive rate of about 50% and a false positive rate of 75% [11]. Adenopathy, fever, and pharyngeal exudate have the highest predictive value for a positive culture and rise in anti-streptolysin O (ASO) titer, and absence of these findings in the presence of cough, rhinorrhea, hoarseness, or conjunctivitis most reliably predicts a negative culture, or positive culture without rise in ASO [11].

Although the cost effectiveness of throat culture has been questioned [12], most clinicians still advocate this procedure as the gold standard to determine appropriate treatment for GABHS. The tonsils, tonsillar crypts, or posterior pharyngeal wall must be swabbed for greatest accuracy. Material obtained by throat swab is placed on a plate containing 5% sheep's blood agar and a bacitracin disk. Inhibition of bacterial growth is approximately 95% accurate for identification of GABHS. The decision about whether to treat pending culture results or to delay treatment until the results are available remains controversial, although some studies suggest that early treatment hastens the clinical response to antibiotics [13].

In the mid-1980s, tests for rapid detection of the group-specific carbohydrate became available. Such assays, which include enzyme immunoassays, latex agglutination tests, and optical immunoassays have simplified the decision to treat at the time of the office visit, and have eliminated the need for additional postvisit communication. However, while most investigators report a specificity of greater than 90% for these tests, recent data suggest a false-positive rate as high as 15% [14]. In addition, their sensitivity is generally in the 60 to 90% range, depending on the clinical environment (*eg*, highly organized clinical trials *vs* hospital clinical laboratories) and varying with the spectrum of disease (higher clinical suspicion correlates with greater sensitivity) [15•]. As a result, many clinicians advocate throat culture for children with suspected streptococcal disease and negative rapid strep tests. Rapid antigen detection is usually more expensive than throat culture, and this technique must still be interpreted with care given the high incidence of posttreatment carriers. Studies also suggest a learning curve effect associated with this diagnostic modality. It should be noted that rapid streptococcal antigen tests were developed for use in the diagnosis of GABHS pharyngotonsillitis; their application as diagnostic tests for GABHS at nonpharyngeal sites is not a Food and Drug Administration–approved use of these tests, although some authors advocate this practice.

Serologic tests are recognized as the definitive means for diagnosing acute streptococcal infection. A rise in ASO titer is usually demonstrable within 1 week of infection and peaks at 3 to 6 weeks. The subsequent decline usually occurs within 6 to 8 weeks but is less reliable and may not occur for months; therefore, a persistent eleva-

tion in ASO titer is not necessarily indicative of ongoing clinical disease. A positive test is defined as a twofold dilution increase in titer between acute and convalescent serum, or any single value above 333 Todd units in children. Response to treatment does not predict a rise in antibody titer [11]. Results should be interpreted with caution, since streptolysin O is also elaborated by group C and G streptococci, ASO titers vary with age, and some antibiotics interfere with the ASO response [16]. Tests for anti-DNAse B and other extracellular antibodies may be useful in patients with suspected sequelae of GABHS infection who do not demonstrate a rise in ASO [16•].

The carrier state

Patients who have been exposed to GABHS may continue to carry the organism asymptotically even after adequate antimicrobial therapy. Carriers are recognized as those individuals who demonstrate a positive culture for the organism but no rise in ASO convalescent titer. This condition is not associated with particular subtypes of the organism or any specific pharyngeal conditions. Carriage rates cited in the literature vary from 3 to 40%, depending on the population studied [17]; however, this figure may be overestimated because of the use of antibiotics, which interfere with the rise in ASO titer. Carriers appear to be at little risk to transmit GABHS, or to develop sequelae of the disease. James *et al.* [18] demonstrated infection of family members by carriers only 9% of the time, and only 40% of those infected developed clinical disease. Thus, only 3.5% of carriers produce clinical disease within their family. It is unknown whether carriers are at increased risk of recurrent pharyngitis.

The high rate of streptococcal carriage complicates the distinction between bacterial and viral pharyngitis in the patient with sore throat and a positive culture. The American Academy of Pediatrics [19] and the Infectious Disease Society of America [20] currently recommend that testing for GABHS should *not* be performed in children with conjunctivitis, cough, hoarseness, coryza, diarrhea, oral ulcerations, or other clinical manifestations highly suggestive of viral infection. A similar approach has recently been suggested for adults with suspected GABHS infection, requiring the presence of two Centor criteria (history of fever, absence of cough, swollen/tender anterior cervical nodes, tonsillar exudate) prior to consideration of GABHS testing [21]. When GABHS infection must be distinguished from nonstreptococcal disease in a carrier, a convalescent ASO titer should be considered.

Treatment of the asymptomatic carrier is desirable in the following situations.

- Carriers in families with a history of rheumatic fever
- Carriers with a history of acute glomerulonephritis

- Carriers in families experiencing ping-pong spread of disease
- Carriers in schools experiencing GABHS epidemics
- Carriers who are food handlers
- Carriers who are hospital workers

In such cases, additional antibiotics, especially clindamycin and rifampin, have demonstrated some efficacy. In refractory cases, tonsillectomy should be considered.

Treatment

Although most upper respiratory infections by GABHS resolve in 3 to 5 days without treatment, studies suggest that antimicrobial therapy prevents suppurative and non-suppurative sequelae including rheumatic fever, and may also hasten clinical improvement [13,22]. Treatment is therefore indicated for all patients with positive rapid tests for the group A antigen. When testing is negative, it is acceptable practice to treat for a few days while formal throat cultures are incubating, providing such treatment is discontinued in the event that final cultures are also negative. When testing is not available, it has been suggested that the presence of all four Centor criteria may be considered an indication for initiation of therapy [21]. Given the low sensitivity of rapid strep testing, a decision not to treat based on a negative test may not be the best choice.

GABHS is sensitive to a number of antibiotics; however, clinical experts consider penicillin the drug of choice in nearly all cases [19,20]. To date, no strains of GABHS acquired *in vivo* have demonstrated penicillin resistance *in vitro*. In addition, a 1993 meta-analysis found no increase in the bacteriologic failure rate with penicillin during the last 40 years [23]. Depot benzathine penicillin G is still advocated by the American Heart Association for primary treatment of GABHS pharyngitis; however, a 10-day course of penicillin orally is the most widely prescribed regimen. Twice-daily dosing by the oral route yields results similar to those obtained with four times a day dosing [24]. A once-daily oral dose of amoxicillin for 10 days also has demonstrated bacteriological efficacy similar to that of oral penicillin dosed three times a day for 10 days [25]. Courses of shorter duration are associated with bacteriologic relapse and are less efficacious in the prevention of rheumatic fever.

During the 1980s, several authors reported a decrease in bacteriologic control rates, attributed primarily to inoculum effects and to increased tolerance to penicillin. Relapses and persistent positive cultures were not associated with significant symptoms or with suppurative or nonsuppurative sequelae, but the goal of eradication to prevent rheumatic fever was not achieved. In a recent study, 35% of 284 patients treated with oral penicillin V and 37% of 271 patients treated with benzathine peni-

cillin G were bacteriologic treatment failures [26••]. Such data support consideration of revised dosing regimens or alternative antimicrobials in the management of GABHS. However, while cephalosporins and macrolides are active against GABHS and their use as treatment for GABHS pharyngitis is considered an acceptable alternative to penicillin, their ability to prevent rheumatic fever remains unproven.

Erythromycin has traditionally been the drug of choice for patients with penicillin allergy; however, increasing prevalence of macrolide-resistant GABHS throughout the world is changing this paradigm. Among pharyngeal cultures from Pittsburgh school children, clonal erythromycin-resistant GABHS was found in 48% [27•]. As has been described in other studies, the unexpectedly high resistance rate was associated with increased local prescribing of macrolide antibiotics during the same period. Azithromycin, used as a 5-day therapy by many clinicians for patients expected to be poorly compliant, may similarly be associated with increasing resistance.

Most patients with positive cultures following treatment are GABHS carriers; these individuals need not be re-treated if their symptoms have resolved. Other explanations for microbiologic failures, including the presence of beta-lactamase producing organisms in the respiratory tract, the presence of GABHS tolerant to penicillin, and the production of inhibitory substances by organisms in the upper respiratory tract that promote persistence of GABHS, have not been convincingly demonstrated [28•,29]. For patients in whom complete bacteriologic clearance is desirable, such as those with a family member with a history of rheumatic fever, a course of clindamycin or a second course of penicillin combined with rifampin may yield increased success. In patients with recurrent symptoms, serotyping may aid in distinguishing bacterial persistence from recurrence. There are no data available regarding the use of antibiotic prophylaxis in these patients, and in such cases tonsillectomy may be most advantageous.

During antimicrobial therapy, patients must be monitored carefully for fluid intake, pain control, and impending suppurative complications such as peritonsillar abscess. Small children may become dehydrated rapidly, and may require hospitalization for administration of fluids intravenously.

Removal of the tonsils as prevention against infection has been a popular concept for decades. Although a number of clinical trials from the early 1900s suggested efficacy of tonsillectomy in reduction of recurrent throat infection, most were of questionable validity due to nonrandom selection of operated subjects, reliance on parents for postoperative data collection, and inappropriate statistical analysis. A series of trials by Paradise *et al.*

at the University of Pittsburgh in the 1970s and 1980s sought to avoid these methodological flaws.

The first two trials [30] were parallel studies with identical design, except that assignment to surgical or non-surgical treatment was random in one and according to parental preference in the other. Throat infection was defined to include one of the following features: temperature greater than 38.3°C, tender cervical adenopathy or nodes greater than 2 cm in size, tonsillar exudate, or positive culture for GABHS. No other attempt was made to determine the cause of the infection. Patients were entered into the study only if they had physician documentation of seven episodes in 1 year, five episodes a year for 2 years, or three episodes a year for 3 years.

Ninety-one patients completed the randomized trial and 96 completed the nonrandom trial. Tonsillectomized patients in the trial with random assignment had 1.85, 1.05, and 0.43 fewer episodes of throat infection than control patients for each of the first three postoperative years, respectively, while those in the parallel nonrandom trial had 1.32, 1.32, and 1.58 fewer episodes; these differences were statistically significant in the first 2 years. However, in both trials, most patients in the nontonsillectomized group were enrolled on the basis of three episodes per year, while most tonsillectomized patients were in the five or seven episodes per year groups. As a result, it is difficult to conclude that the lower postoperative frequency of infection in the tonsillectomy group is due to the surgical intervention rather than to spontaneous improvement of patients affected for a shorter period. Furthermore, moderate and severe episodes were rare even in the control groups, and there was no statistical difference in total days spent with sore throat between the surgical and nonsurgical groups. On the other hand, the effect of tonsillectomy may have been understated due to transfer of severely affected patients from the nonsurgical to the surgical groups.

Based on these studies, tonsillectomy may offer a small advantage in the treatment of children in whom a pattern of severe recurrent pharyngotonsillitis has been well documented. The authors themselves state, however, that a decision whether or not to perform tonsillectomy should consider risks, preferences, and anxieties of parent and child, school absences due to illness, accessibility to health care services, cost, and availability of surgical facilities.

In a study published recently [31••], Paradise *et al.* report the results of two trials in which the entrance criteria from the first two studies were made less stringent. Patients entering the study had a lower frequency of infection or less severe episodes, or lacked the documentation of episodes required in the first study. These patients were grouped together and then assessed for indications

for adenoidectomy. Those without such indications (N = 177) were assigned to the first trial and randomized to undergo tonsillectomy, adenotonsillectomy, or no surgery. Patients with indications for adenoidectomy (N = 151) were assigned to the second trial and underwent adenotonsillectomy or no surgery. In both trials, the frequency of infection in both the surgical and nonsurgical groups again dropped, although the decrease was marginally greater (approximately one episode per year) in the surgical groups. However, control subjects in both trials again developed far less than one episode of moderate or severe pharyngitis per year. Although the data were not dramatically different from those in the initial publication, in this study, the authors concluded that the small potential benefits of surgery did not justify the associated risk and expense. Furthermore, performing adenoidectomy in addition to tonsillectomy conferred no additional advantage in controlling throat infections when compared with tonsillectomy alone.

There are currently no clinical trials to support or refute the efficacy of tonsillectomy for streptococcal carriers with or without chronic sore throat.

References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:

- Of special interest
 - Of outstanding interest
- 1 Markowitz M: Changing epidemiology of group A streptococcal infections. *Pediatr Infect Dis J* 1994, 13:557–560.
 - 2 Kaplan EL: The group A streptococcal upper respiratory tract carrier state: an enigma. *J Pediatr* 1980, 97:337–345.
 - 3 Wilson KS, Maroney SA, Gander RM: The family pet as an unlikely source of group A beta-hemolytic streptococcal infection in humans. *Pediatr Infect Dis J* 1995, 14:372–375.
 - 4 Fujimori I, Kikushima K, Hisamatsu K, et al.: Interaction between oral alpha-streptococci and group A streptococci in patients with tonsillitis. *Ann Otol Rhinol Laryngol* 1997, 106:571–574.
 - 5 Facklam RF, Martin DR, Lovgren M, et al.: Extension of the Lancefield classification for group A streptococci by addition of 22 new M protein gene sequence types from clinical isolates: emm103 to emm124. *Clin Infect Dis* 2002, 34:28–38.
 - 6 Haukness HA, Tanz RR, Thomson RB Jr, et al.: The heterogeneity of endemic community pediatric group A streptococcal pharyngeal isolates and their relationship to invasive isolates. *J Infect Dis* 2002, 185:915–920.
- This study suggests that children with pharyngitis may represent a reservoir for GABHS strains with invasive potential.
- 7 Gerber MA: Antibiotic resistance: relationship to persistence of group A streptococci in the upper respiratory tract. *Pediatrics* 1996, 97:971–975.
 - 8 Kaplan EL, Gerber MA: Group A, group C, and group G beta-hemolytic streptococcal infections. In *Textbook of Pediatric Infectious Diseases*, 4th edition. Edited by Feigin RD, Cherry JD. Philadelphia: WB Saunders; 1998:1076–1088.
 - 9 Murphy ML, Pichichero ME: Prospective identification and treatment of children with pediatric autoimmune neuropsychiatric disorder associated with group A streptococcal infection (PANDAS). *Arch Pediatr Adolesc Med* 2002, 156:356–361.
- This is the first prospective study of the association between PANDAS and GABHS pharyngitis and the response to antimicrobial therapy.
- 10 Orvidas LJ, Slattery MJ: Pediatric autoimmune neuropsychiatric disorders and streptococcal infections: role of the otolaryngologist. *Laryngoscope* 2001, 111:1515–1519.
- This paper is an excellent review of PANDAS for the otolaryngologist.

454 Pediatric otolaryngology

- 11 Kline JA, Runge JW: Streptococcal pharyngitis: a review of pathophysiology, diagnosis, and management. *J Emerg Med* 1994, 12:665-680.
- 12 Tompkins RK, Burnes DC, Cable WE: An analysis of the cost-effectiveness of pharyngitis management and acute rheumatic fever prevention. *Ann Intern Med* 1977, 86:481-492.
- 13 Randolph MF, Gerber MA, DeMeo KK, et al.: Effect of antibiotic therapy on the clinical course of streptococcal pharyngitis. *J Pediatr* 1985, 106:870-875.
- 14 Johnson DR, Kaplan EL: False-positive rapid antigen detection test results: reduced specificity in the absence of group A streptococci in the upper respiratory tract. *J Infect Dis* 2001, 183:1135-1137.
- 15 DiMatteo LA, Lowenstein SR, Brimhall B, et al.: The relationship between the clinical features of pharyngitis and the sensitivity of a rapid antigen test: evidence of spectrum bias. *Ann Emerg Med* 2001, 38:648-652.
- This study suggests that sensitivity of rapid antigen testing varies with clinical severity, and that in patients with three or four clinical criteria for GABHS, culture confirmation of negative rapid strep tests may not be necessary.
- 16 Shet A, Kaplan EL: Clinical use and interpretation of group A streptococcal antibody tests: a practical approach for the pediatrician or primary care physician. *Pediatr Infect Dis J* 2002, 21:420-430.
- The authors review use and interpretation of ASO, anti-DNAse, and other antibody tests for GABHS infection.
- 17 Pichichero ME, Marsocci SM, Murphy ML, et al.: Incidence of streptococcal carriers in private pediatric practice. *Arch Pediatr Adolesc Med* 1999, 153:624-628.
- 18 James WE, Badger GF, Dingle JH: A study of illnesses in a group of Cleveland families, XIX: The epidemiology of the acquisition of group A streptococci and of associated illness. *N Engl J Med* 1960, 262:687-694.
- 19 American Academy of Pediatrics: Group A streptococcal infections. In 2000 Redbook—Report of the Committee on Infectious Diseases, 25th ed. Edited by Pickering LK. Elk Grove Village, IL: American Academy of Pediatrics; 2000:526-536.
- 20 Bisno AL, Gerber MA, Gwaltney JM Jr, et al.: Diagnosis and management of group A streptococcal pharyngitis: a practice guideline. *Clin Infect Dis* 1997, 25:574-583.
- 21 Cooper RJ, Hoffman JR, Bartlett JG, et al.: Principles of appropriate antibiotic use for acute pharyngitis in adults: background. *Ann Intern Med* 2001, 134:509-517.
- 22 Pichichero ME, Disney FA, Talpey WB, et al.: Adverse and beneficial effects of immediate treatment of group A beta-hemolytic streptococcal pharyngitis with penicillin. *Pediatr Infect Dis J* 1987, 6:635-643.
- 23 Markowitz M, Gerber MA, Kaplan EL: Treatment of streptococcal pharyngotonsillitis: reports of penicillin's demise are premature. *J Pediatr* 1993, 123:679-685.
- 24 Gerber MA, Spadaccini LJ, Wright LL, et al.: Twice-daily penicillin in the treatment of streptococcal pharyngitis. *Am J Dis Child*, 1985, 139:1145-1148.
- 25 Feder HM Jr, Gerber MA, Randolph MF, et al.: Once-daily therapy for streptococcal pharyngitis with amoxicillin. *Pediatrics* 1999, 103:47-51.
- 26 Kaplan EL, Johnson DR. Unexplained reduced microbiological efficacy of intramuscular benzathine penicillin G and of oral penicillin V in eradication of group A streptococci from children with acute pharyngitis. *Pediatrics* 2001, 108:1180-1186.
- This important study reports the persistence of GABHS in more than 35% of patients prescribed penicillin, suggesting a possible role for adjustment of dosing or alternative antimicrobials therapy.
- 27 Martin JM, Green ML, Barbadora KA, et al.: Erythromycin-resistant group A streptococci in children in Pittsburgh. *N Engl J Med* 2002, 346:1200-1206.
- This study reports the emergence of erythromycin-resistant strains of GABHS, which may impact the choice of antimicrobial therapy for GABHS in patient with penicillin allergy.
- 28 Gerber MA, Tanz RR, Kabat W, et al.: Potential mechanisms for failure to eradicate group A streptococci from the pharynx. *Pediatrics* 1999, 104:911-917.
- 29 Brook I: Failure of penicillin to eradicate group A beta-hemolytic streptococcal tonsillitis: causes and management. *J Otolaryngol* 2001, 30:324-329.
- The author provides an excellent summary of mechanisms of penicillin failure in GABHS infection.
- 30 Paradise JL, Bluestone CD, Bachman RZ, et al.: Efficacy of tonsillectomy for recurrent throat infection in severely affected children. *N Engl J Med* 1984, 310:674-683.
- 31 Paradise JL, Bluestone CD, Colborn DK, et al.: Tonsillectomy and adenotonsillectomy for recurrent throat infection in moderately affected children. *Pediatrics* 2002, 110:7-15.
- This study presents two trials in which the authors relax the stringent entrance criteria used in their 1984 paper. The results suggest that in less severely affected patients with recurrent pharyngitis, tonsillectomy confers marginal benefit, and that the small advantages of the procedure may not justify the inherent risk or cost. The authors also demonstrated no additional efficacy when adenoidectomy was performed with tonsillectomy.